Helmholtz Munich

Research Director Helmholtz Munich, Full Professor and Chair of Experimental Genetics Technical University Munich Germany, Director of the Institute of Experimental Genetics Helmholtz Munich

+49 89 3187 3502 Email meBuilding/Room: 35.14 / 317

Click and View

Prof. Hrabě de Angelis’ areas of research include genetics, diabetes, phenotyping and data mining.

Martin Hrabě de Angelis studied biology at Philipps University in Marburg and completed his PhD on the influence of growth factors on early embryonic development in 1994. During his time as a postdoctoral researcher (1994 – 1997) at the internationally recognized Jackson Laboratory in Bar Harbor (USA), he examined the Delta/Notch signaling pathway and somitogenesis in mouse models. Deciphering the genetic underpinning for pattern formation of the body axis has been a major focus. Already at that time modelling human health and disease has been of major interest.

In 1997 he returned to Germany and headed the working group “Functional Genetics” at the Institute for Mammalian Genetics GSF, Munich. Together with Prof. Rudi Balling and colleagues he successfully performed the first comprehensive ENU-mutagenesis screen for disease models, resulting in great many new models, which have been used in the own laboratory and world-wide.

In 2001, Martin founded the world first Mouse Clinic (German Mouse Clinic) for the systemic analysis of mouse models for human disease including a special focus on metabolism. This was possible in his new position as director of the Institute of Experimental Genetics at Helmholtz Munich (German Research Center for Environmental Health). In 2003, he was appointed to the Chair of Experimental Genetics at Technical University Munich. He is also the director of the European research consortium "INFRAFRONTIER".

Hrabě de Angelis and colleagues have shown that dietary obesity and diabetes mellitus can be epigenetically inherited from the offspring via egg cells as well as sperm. By studying knockout mice, each of which lacked a precisely selected gene, he succeeded in identifying 51 unknown genes that could play an important role in the development of metabolic diseases and diabetes. His published research articles, have been cited over 42 000 times. Martin Hrabě de Angelis directs national and international research projects. He is co-founder and board member of the German Center for Diabetes Research (DZD, 2009). He is also elected member of the National Academy of Science (Leopoldina)

Speaker and member of the board: German Center for Diabetes Research (DZD)
CEA/CSO: INFRAFRONTIER Ltd. Non for profit
Member of the Excecutive Board IMPC
Co-founder of two biotech companies

Fields of Work and Expertise

Metabolism & DiabetesLarge Scale Functional Genomics/GeneticsEpigeneticsData Mining

Professional Background

Since 2020

Research Director Helmholtz Zentrum München GmbH

2003

Full Professor (W3) and Chair of Experimental Genetics Technical University München Germany

2000

Director Institute of Experimental Genetics, Helmholtz Zentrum München GmbH

1997-2000

1997-2000: Independent group leader within the German Human Genome Project (DHGP) and coordinator of the ENU mutagenesis project at the Institute of Mammalian Genetics, GSF, Munich

1994-1997

Postdoctoral fellow at Jackson Laboratory, Bar Harbor, ME, USA (DFG and NIH stipend)

1994

PhD in Biology at Philipps University Marburg (summa cum laude)

1990

Study Biology, Sports, Pedagogy at Philipps University Marburg, (State examination passed with distinction)

Honors and Awards

Paul Langerhans Medal – Highest recognition of the DDG (German Diabetes Society)
2021
IMPC award of excellence
2019
Member of the National Academy of Sciences LEOPOLDINA
2018
Dr. med. honoris causa Technical University Dresden Germany
2018
Dr. vet. med. honoris causa. Ludwig Maximilian University Munich Germany
2017
Dr. med. honoris causa Eberhard-Karls University Tübingen Germany
2016
Paula und Richard von Hertwig award for interdisciplinary research
2003 & 2010
JAX/NIH stipend postdoctoral fellow
1996-97
DFG Stipend as postdoctoral fellow
1994-96
Summa cum laude for overall performance PhD
1994

See all Publications of Martin Hrabě de Angelis

Nature Cardiovascular Research 1(2) 157-173 (2022)

Spielmann N, et al., Hrabě de Angelis M:

Extensive identification of genes involved in congenital and structural heart disorders and cardiomyopathy.

EMBO Mol Med e14397, doi:10.15252/emmm.202114397 (2021)

Vidali S, Gerlini R, et al., Gailus-Durner V, Hrabě de Angelis M:

Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes.

Commun Biology 3:628, https://doi.org/10.1038/s42003-020-01337-x. (2020)

Chhabra N, et al., Hrabě de Angelis M:

PAX6 mutation alters circadian rhythm and β cell function in mice without affecting glucose tolerance.

Proc Natl Acad Sci U S A, DOI: 10.1073/pnas.1819825116 (2019)

Abe K, Cox A, Takamatsu N, et al., Hrabě de Angelis M:

Gain-of-function mutations in a member of the Src family kinases cause autoinflammatory bone disease in mice and humans.

Nat Commun 9:288, DOI: 10.1038/s41467-017-01995-2 (2018)

Rozman J, Rathkolb B, et al., Hrabě de Angelis M:

Identification of genetic elements in metabolism by high-througput mouse phenotyping.

Nature Genet 48,497-499 DOI:10.1038/ng.3527 (2016) (* equal contribution)

Huypens P, et al., Hrabě de Angelis M, Beckers J:

Epigenetic germline inheritance of diet-induced obesity and insulin resistance.

Nat Genet 47(9), 969-978 (2015)

Hrabě de Angelis M, et al., Brown SD:

Analysis of mammalian gene function through broad-based phenotypic screens across a consortium of mouse clinics.

Diabetes, DOI: 10.23377db14-0393 (2014)

Neschen S, et al. Hrabě de Angelis M:

Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 (SGLT2) inhibitor by suppressing endogenous glucose production in diabetic mice.

AdobeStock_327779924 3D illustration of Coronavirus cells

Chair of Task Force “Fight COVID19 @ Helmholtz Munich” (since 2020)

President of the International Mammalian Genome Society (IMGS) (2017-2019)

Member and Chair (since 2019) of the RIKEN Bioresource Research Center Advisory Board, Japan (since 2014)

Member of the Scientific Advisory Board MRC Harwell, UK (since 2014)

Member of external Council Board Karolinska Institute, Sweden (since 2014)

Member of the executive committee of the International Mouse Phenotyping Consortium (IMPC) (since 2009)

Founding member and chair of the board of the “German Center for Diabetes Research e.V.” (DZD) (since 2009)

Martin Hrabě de Angelis, Prof. Dr. Dr. h.c. mult.